A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
NCT05607160 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82
Last updated 2024-04-12
Summary
Primary objective:
\- Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice
Secondary objective:
\- Treatment satisfaction
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Sponsors & Collaborators
-
Sanofi
lead INDUSTRY
Principal Investigators
-
Clinical Sciences & Operations · Sanofi
Eligibility
- Min Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-10-05
- Primary Completion
- 2023-12-11
- Completion
- 2023-12-11
Countries
- Germany
Related Clinical Trials
-
Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
NCT03760991 · Status: COMPLETED · Phase: PHASE4
- Type 2 Diabetes Mellitus
-
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
NCT01203111 · Status: COMPLETED · Phase: PHASE4
- Diabetes Mellitus, Type 2
-
A Study in Patients With Type 2 Diabetes Mellitus
NCT01435616 · Status: COMPLETED · Phase: PHASE3
- Diabetes Mellitus, Type 2
-
Insulin Glulisine in Diabetes Mellitus, Type 2
NCT00174668 · Status: COMPLETED · Phase: PHASE3
- Diabetes Mellitus, Type 2
-
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
NCT01127269 · Status: COMPLETED · Phase: PHASE4
- Diabetes Mellitus, Type 2
More Related Trials
-
Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus
NCT00565162 ·Status: COMPLETED ·Phase: PHASE4
-
Insulin Glargine in Type 2 Diabetic Patients
NCT00347100 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
NCT04957914 ·Status: COMPLETED ·Phase: PHASE1
-
20 Week Bridging Study in Type II DM
NCT00563225 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
NCT02058160 ·Status: COMPLETED ·Phase: PHASE3
-
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
NCT06671587 ·Status: RECRUITING ·Phase: PHASE4
-
Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement
NCT00354939 ·Status: COMPLETED ·Phase: PHASE4
-
Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
NCT03371082 ·Status: COMPLETED ·Phase: PHASE3
-
A Study for Patients With Type 2 Diabetes
NCT01027871 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients
NCT00859079 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin
NCT00693771 ·Status: COMPLETED ·Phase: PHASE4
-
Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM
NCT02227212 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
NCT03798054 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
NCT05462756 ·Status: COMPLETED ·Phase: PHASE3
-
Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
NCT01240200 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
NCT02320721 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)
NCT00653341 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
NCT01499082 ·Status: COMPLETED ·Phase: PHASE3
-
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
NCT00135057 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)
NCT00659477 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
NCT07307235 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
NCT03798080 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure
NCT01461577 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
NCT01117350 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
NCT01658579 ·Status: COMPLETED ·Phase: PHASE2